<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5177">
  <stage>Registered</stage>
  <submitdate>11/08/2015</submitdate>
  <approvaldate>11/08/2015</approvaldate>
  <nctid>NCT02564770</nctid>
  <trial_identification>
    <studytitle>A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia</studytitle>
    <scientifictitle>A Retrospective Chart Review of the Use of MabThera (Rituximab) for the Treatment of Rheumatoid Arthritis (RA) in Australian Rheumatology Practice</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ML28321</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rheumatoid arthritis (RA) participants - Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Factors leading to Therapeutic decision to use rituximab</outcome>
      <timepoint>Up to end of study (approximately 1 month)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Erythrocyte sedimentation rate</outcome>
      <timepoint>Baseline and most recent visits (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Immunoglobulin levels</outcome>
      <timepoint>Baseline and most recent visits (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with positive or negative results for rheumatoid factor</outcome>
      <timepoint>Up to end of study (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with positive or negative results for anti-cyclic citrullinated peptide antibody</outcome>
      <timepoint>Up to end of study (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with positive or negative results for anti-nuclear antibodies</outcome>
      <timepoint>Up to end of study (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease activity score (DAS28)</outcome>
      <timepoint>At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tender joint count (TJC)</outcome>
      <timepoint>At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Swollen joint count (SJC)</outcome>
      <timepoint>At baseline visit (most recent visit prior to MabThera treatment) and at most recent visit prior to chart review (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of treatment with rituximab</outcome>
      <timepoint>From first dose to most recent rituximab infusion (approximately 1 month)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in C-reactive protein</outcome>
      <timepoint>Baseline and most recent visits (approximately 1 month)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Greater than or equal to (&gt;=) 18 years of age at the time of data collection

          -  RA diagnosed by a rheumatologist

          -  Treatment with rituximab for RA</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participants whose primary diagnosis and indication for rituximab treatment is a
             condition other than RA

          -  Participants who have been treated with an experimental agent for RA which is not
             currently approved for the treatment of RA in Australia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>167</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Geelong</hospital>
    <postcode>3220 - Geelong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Roche Products Pty Ltd (Australia)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a cross-sectional, observational study examining the factors leading to the
      therapeutic decision to use MabThera (rituximab) in participants with RA. Routine
      rheumatology clinical practice data of participants who are being or have been treated with
      rituximab for RA will be collected and analysed in this chart review.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02564770</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>